New Report Suggests that Roche is Less Exposed to Biosimilars than Amgen

November 30, 2011
Top Quote Excluding Mabthera, Roche's other brands will face biosimilar competition only after 2019. As a result, the company will suffer most of its brand erosion post-2020. End Quote
  • (1888PressRelease) November 30, 2011 - In 2020, Roche, the world's largest biotech company and global investor in R&D is expected to lose US sales worth $2.5 billion as a result of biosimilar competition. IMARC Group, one of the world's leading research and advisory firms, in its new report "Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)" finds that five of the Roche's blockbuster biologicals (Avastin, Herceptin, Mabthera, Lucentis and Xolair) face biosimilar competition during 2011-2020. Projections from the report that are based on an extensive primary and secondary research suggest that the combined sales of these five drugs will decline from $10.7 billion in 2010 to $8.2 billion in 2020.

    Despite this significant decline, Roche is still expected to be much better off than some of its other peers such as Amgen - atleast in the short term. Findings from the study suggest the excluding Mabthera, the company's other four brands will face biosimilar competition only during 2019-2020. As a result, Roche will suffer most of its brand erosion post-2020. The study finds that unlike Roche, Amgen is expected to witness biosimilar competition in all four of its brands (Enbrel, Epogen, Neupogen, and Neulasta) during 2013-2015. Projections From the report suggest that the combined sales of these four products will reduce from $10.6 billion in 2010 to just $1.4 billion in 2020.

    IMARC's new report entitled "Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)" provides an analytical and statistical insight into the US biosimilar market. The study, that has been undertaken using desk-based as well as qualitative primary research, provides and draws upon analysis of six aspects of the US biosimilar market.

    Key Aspects Analyzed:

    Evaluating the Current Market Landscape of Biosimilars:
    • Identification of currently marketed biosimilars and their historical performance
    • Identifying the reasons for the slow uptake of currently marketed biosimilars
    • Analyzing historical data to formulate conclusions on the future growth and market trends of biosimilars

    Evaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars:
    • Analyzing historical time series data on price, volume and sales erosion in the US & Europe
    • Analyzing previous models and assumptions on price and volume erosion caused by biosimilars
    • Evaluating and comparing price and volume erosion created by biosimilars vis-a-vis by small molecule generics
    • Evaluating and comparing price, volume and sales erosion by biosimilars across various biological classes

    Evaluating the Market Potential of Biosimilars Across Various Molecules:
    Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin Alfa (Epogen/Eprex), Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin Lispro (Humalog), Insulin Glargine (Lantus), Insulin Detemir (Levemir), Interferon Beta-1A (Avonex), Interferon Beta-1A (Rebif), Interferon Beta-1B (Betaferon), Bevacizumab (Avastin), Trastuzumab (Herceptin), Rituximab (Mabthera/Rituxan), Cetuximab (Erbitux), Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab (Xolair) and Natalizumab (Tysabri).

    Focus of the Analysis for Each Molecule:
    • Historical background and overview
    • Historical brand sales
    • Patent position
    • Competing products
    • Biosimilars in pipeline
    • Brand and biosimilar sales forecasts

    Evaluating the Sales of Biosimilars across Various Indications:
    Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and Growth Deficiency
    Focus of the Analysis for Each Indication:
    • Historical brand sales
    • Brand and biosimilar sales forecasts
    • Indication wise breakup of molecules

    Evaluating the Biosimilar Competitive Landscape:
    • Identifying branded biological manufacturers that expect the highest amount of erosion from biosimilars
    • Identifying biosimilar manufacturers and their pipelines
    Understanding the Current Legislation on Biosimilars:
    • An insight into the Biologics Price Competition and Innovation Act
    • An insight into the key biosimilar issues that still remain unaddressed
    • Interchangeability and Substitutability
    • Data Exclusivity
    • Statutory provisions for dealing with patent litigations

    To buy the complete report or to get a free sample, please contact:
    IMARC Group Asia
    Email: apac ( @ ) imarcgroup dot com
    Phone: +91-120-425-6531
    IMARC Group North America
    Email: america ( @ ) imarcgroup dot com
    Phone: +1-631-791-1145
    To know more please visit: http://www.imarcgroup.com/

    ###
space
space
  • FB Icon Twitter Icon In-Icon
Contact Information
  • Krishna Sharma
  • Imarc Group
  • 21/601 Eastend Apartment Mayur Vihar Phase-1 Extention Delhi-110096, India
  • 110096
  • Voice: 91-11-43095788
  • Visit our Site
Over Satisfied Users & Approved Press Releases
© Copyright 2005-2024, 1888 Press Release. All Rights Reserved